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the original work isObjective: Effects of transient combination antiretroviral treatment (cART) initiated
during early HIV infection (EHI) remain unclear. We investigate whether this inter-
vention affects viral suppression and CD4þ cell count increase following its reinitiation
in chronic infection (CHI).
Design: Longitudinal observational study.
Methods: We identified adult patients from Concerted Action of Seroconversion to
AIDS and Death in Europe who seroconverted after 1/1/2000, had a 12 months or less
HIV test interval and initiated cART from naive. We classified individuals as ‘pretreated
in EHI’ if treated within 6 months of seroconversion, interrupted for at least 12 weeks,
and reinitiated during CHI. Statistical analysis was performed using survival analysis
methods and mixed models.
Results: Pretreated and initiated in CHI groups comprised 202 and 4263 individuals,
with median follow-up after CHI treatment 4.5 and 3 years, respectively. Both groups
had similar virologic response and relapse rates (P¼0.585 and P¼0.206) but pre-
treated individuals restarted treatment with higher baseline CD4þ cell count (80cells/
ml; P<0.001) and retained significantly higher CD4þ cell count for more than 3 years
after treatment (re)initiation. Assuming common baseline CD4þ cell count, differences
in CD4þ cell count slopes were nonsignificant. Immunovirologic response to CHI
treatment was not associated with timing or duration of the transient treatment.
Conclusion: Although treatment interruptions are not recommended, stopping cART
initiated in EHI does not seem to reduce the chance of a successful outcome of treatment
in CHI. Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2016, 30:879–888Keywords: early/primary HIV infection, immunologic response, transient
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880 AIDS 2016, Vol 30 No 6IntroductionFor the vast majority of untreated HIV-positive
individuals, the course of disease is characterized by
sustained viral replication and progressive CD4þ T-cell
depletion [1]. The ability of combination antiretroviral
treatment (cART) to suppress viral load and boost the
immune system is well established [2]. Unfortunately,
cART cannot eradicate HIV [3], and treatment inter-
ruption is usually followed by rapid viral rebound, CD4þ
T-cells loss [4], and increased risk of morbidity and
mortality [5]. Commitment to cART is, therefore,
lifelong.
It has been shown that immune response during acute
HIV-1 infection plays an important role on subsequent
disease progression [6], and that cART administered
during that period may preserve HIV-1–specific immune
response [7–9], reduce viral diversity and reservoir size
[10,11], and stimulate immune restoration [12,13]. Thus,
it was hypothesized that transient cART during early HIV
infection (EHI) could lead to prolonged control of viral
replication, even after its interruption.
Several studies have focused on the effect of transient
cART initiated soon after seroconversion [14–25].
However, despite discrepancies in findings, it is clear
that, even in the best case scenario, a small proportion of
these early-treated individuals maintain long-term viral
suppression after cART cessation.
International guidelines, specifically regarding treatment
of acute or early HIV-1 infection, remain unclear. United
States Department of Health and Human Services
guidelines recommend that cART should be offered to
all patients with EHI [26]. European AIDS Clinical
Society guidelines suggest that treatment should be
considered and actively discussed [27]. WHO guidelines
do not contain any relevant recommendations for acute/
early infection [28].
In practice, a substantial number of HIV-positive persons
diagnosed soon after seroconversion initiate cART
immediately, even without having a low CD4þ cell
count (i.e. with >500 CD4þ cells/ml), or AIDS-related
conditions. Despite the contraindications for treatment
interruption, many do stop, and the vast majority loses the
virologic and immunologic advantages gained while on
cART. These individuals will most likely have to reinitiate
treatment later, during chronic infection (CHI). Whether
the response to cART reinitiated in CHI for these
individuals with prior transient cARTexperience in EHI
differs from that of those initiating in CHI, has not been
sufficiently evaluated.
The main objective of this study was to assess if transient
cART, administered during EHI, has any effect on
response to cART reinitiated during CHI. Additionally,differential effects associated with the timing and duration
of transient cART initiated soon after seroconversion
was investigated.Methods
CASCADE (Concerted Action of Seroconversion to
AIDS and Death in Europe – http://www.cascade-
collaboration.org/) is a collaboration of 28 cohorts of
individuals with well-estimated dates of HIV seroconver-
sion [29]. We used data pooled in September 2014 within
EuroCoord (www.EuroCoord.net). All collaborating
cohorts received approval from their regulatory or
national ethics review boards.
In CASCADE, seroconversion dates are estimated as the
midpoint between the last documented negative and first-
positive HIV antibody test dates for the majority of
participants (87.8%) with the interval between these tests
being 3 years or less. For the remaining individuals,
seroconversion dates are estimated through laboratory
methods (PCR positivity in the absence of HIV
antibodies or antigen positivity with fewer than four
bands on western blot; 10.1%), or as the date of
seroconversion illness with both an earlier negative and a
later positive HIV test performed within 3 years or
less (2.1%).
Eligible individuals were those who seroconverted in
or after 2000, were at least 15 years old, had their
seroconversion date determined through the midpoint
(test interval 12 months) or laboratory methods, and
had initiated cART from naive. Individuals followed-up
in African cohorts and those who started cART in EHI
with AIDS or with a prior CD4þ cell count of less than
350 cells/ml were excluded. Individuals, who started
cART during EHI were eligible only if they remained on
treatment for at least 12 weeks and less than 2 years,
interrupted all cART drugs for at least 12 weeks and
reinitiated later during CHI. Those who received cART
during CHI, for less than 8 weeks or did not have CD4þ
cell count and viral load measurements at baseline
(i.e. cART initiation in CHI) and while on treatment,
were excluded.
We defined EHI as the first 6 months after seroconversion
[26] and CHI thereafter. Virological response was defined
as two consecutive viral load measurements less than
50 copies/ml. Virological relapse was defined as having
two consecutive viral load measurements at least
50 copies/ml or just one at least 100 copies/ml, after
virological response. cART was defined as a regimen
containing at least three antiretroviral agents from at least
two different classes or combinations of at least three
nucleoside reverse transcriptase inhibitors with one of
them being abacavir or tenofovir.
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Table 1. Demographic and clinical characteristics of HIV-1 seroconverters treated in chronic infection by whether they had initiated
combination antiretroviral treatment within 6 months of seroconversion (pretreated in early HIV infection) or not (not-pretreated in early HIV
infection).
Group
Pretreated in
EHI (n¼202)
Not-pretreated
in EHI (n¼4263)
Overall
(N¼4465) P value
Female sex 21 (10.4) 533 (12.5) 554 (12.4) 0.375
Risk group 0.140
MSM 154 (76.2) 3193 (74.9) 3347 (75.0)
IDU 1 (0.5) 135 (3.2) 136 (3.0)
MSW 38 (18.8) 798 (18.7) 836 (18.7)
Other-unknown 9 (4.5) 137 (3.2) 146 (3.3)
Ethnic group <0.001
White 131 (64.9) 1668 (39.1) 1799 (40.3)
Black 7 (3.5) 103 (2.4) 110 (2.5)
Hispanic 0 (0.0) 27 (0.6) 27 (0.6)
Asian 4 (2.0) 41 (1.0) 45 (1.0)
Mixed/other 0 (0.0) 21 (0.5) 21 (0.5)
Unknown 60 (29.7) 2403 (56.4) 2463 (55.2)
Seroconversion determination and HIV test interval <0.001
Midpoint (>30 days) 69 (34.2) 3230 (75.8) 3299 (73.9)
Midpoint (30 days) 14 (6.9) 121 (2.8) 135 (3.0)
Laboratory evidence 109 (54.0) 763 (17.9) 872 (19.5)
Seroconversion illness 10 (5.0) 149 (3.5) 159 (3.6)
Type of EHI-cART
NNRTI 42 (20.8)
Boosted PI 141 (69.8)
Unboosted PI 12 (5.9)
Other 7 (3.5)
AIDS before CHI-cART 11 (5.4) 153 (3.6) 164 (3.7) 0.170
Type of CHI-cART 0.377
NNRTI 87 (43.1) 1994 (46.8) 2081 (46.6)
Boosted PI 100 (49.5) 1875 (44.0) 1975 (44.2)
Unboosted PI 6 (3.0) 120 (2.8) 126 (2.8) 
Other 9 (4.5) 274 (6.4) 283 (6.3)
Age at seroconversion (years) 35.4 (30.1, 42.0) 33.6 (27.5, 40.9) 33.7 (27.6, 40.9) 0.009
Year of seroconversion 2003 (2002, 2004) 2006 (2003, 2008) 2006 (2003, 2008) <0.001
Age at CHI-cART (years) 39.7 (33.9, 46.4) 36.4 (30.2, 43.6) 36.5 (30.3, 43.7) <0.001
Months from seroconversion to EHI-cART 0.6 (0.3, 2.3)
EHI-cART duration (months) 11.0 (5.7, 14.6) 11.0 (5.7, 14.6)
TI duration of pretreated (months) 35.4 (17.8, 57.2) 35.4 (17.8, 57.2)
Months from seroconversion to CHI-cART 48.1 (30.0, 69.5) 24.2 (13.0, 43.7) 24.9 (13.4, 45.1) <0.001
Year of CHI-cART 2008 (2006, 2010) 2009 (2007, 2011) 2009 (2007, 2011) <0.001
Follow-up after CHI-cART (months) 53.8 (30.2, 76.8) 33.9 (16.4, 58.3) 34.7 (16.6, 59.4) <0.001
1st CD4þ after seroconversion (cells/ml) 540 (4512, 672) 486 (363, 637) 489 (367, 639) <0.001
CHI-cART baseline CD4þ (cells/ml) 360 (276, 480) 329 (250, 428) 330 (251, 431) <0.001
1st viral load after seroconversion (log10 copies/ml) 5.3 (4.7, 5.9) 4.7 (4.1, 5.3) 4.8 (4.1, 5.3) <0.001
CHI-cART baseline viral load (log10 copies/ml) 4.8 (4.3, 5.2) 4.7 (4.2, 5.2) 4.7 (4.2, 5.2) 0.180
Numbers are N (%) or median (IQR). P-values based on (categorical variables) and Mann–Whitney (continuous variables) tests. cART, combined
antiretroviral treatment; CHI chronic HIV infection; EHI, early HIV infection; IDU, injection drug users, IQR, interquartile range; MSM, men who
have sex with men; MSW, sex between men and women; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.Statistical methods
Virologic response and relapse rates were analyzed using
survival analysis methods for interval censored data
(nonparametric maximum likelihood estimator of the
survivor function and accelerated failure time models
[30]) as the exact times of these events were only known
to lie between the times of two successive viral load
measurements. CD4þ cell count dynamics after (re)ini-
tiation of cART during CHI were analyzed using a
piecewise linear mixed model with different slopes for the
first 3 months, months 3–30 and after the 30th month of
treatment after a square root transformation. A post-
estimation adjustment was used to compare the two
groups in terms of CD4þ cell count evolution, assuming acommon baseline CD4þ cell count [31]. Age, sex, risk
group, ethnic group, year of seroconversion, acute
infection, previous AIDS, seroconversion determination
method, year of treatment initiation, and baseline marker
levels were considered as potential confounders.Results
Of 31 482 seroconverters in CASCADE, 24 482 did not
meet the inclusion criteria (Figure S1, http://links.lww.-
com/QAD/A853). The final study population consisted
of 4465 individuals, of whom 202 received transient cART
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Fig. 1. Cross-sectional distribution of (a) viral load, (b)
virologic response and (c) virologic relapse after combi-
nation antiretroviral treatment initiation during chronic
HIV infection (CHI) for individuals pretreated in early
HIV infection (EHI) and previously untreated individuals.during EHI and restarted cART in CHI (‘Pretreated in
EHI’ group). The remaining 4263 individuals who
initiated cART in CHI will be referred to as the
‘Previously untreated’ group.
Demographic and clinical characteristics are presented
in Table 1. The two groups were comparable in terms of
sex, risk group, type of CHI-cART regimen, and CHI-
cART baseline viral load distributions. Those pretreated
in EHI tended to be slightly older, acquired HIV in earlier
years, and had higher viral load and CD4þ cell count close
to seroconversion, higher CD4þ cell count at the start of
CHI-cART, and longer post CHI-cART follow-up.
CHI-cART regimens for both groups were almost
equally based on nonnucleoside reverse transcriptase
inhibitor (NNRTIs) or boosted protease inhibitors (PIs),
with only a small proportion starting a triple NRTI or
fusion/maturation inhibitor-based regimen. Finally, the
time of cART (re)initiation in CHI, relative to
seroconversion, was longer in those pretreated in EHI
compared with those previously untreated.
Estimation of the seroconversion date among pretreated
individuals was mostly accurate as 65.8% of them had a
seroconversion illness, laboratory evidence of seroconver-
sion or an HIV test interval of less than a month (Table 1).
Among those with a longer HIV test interval (n¼ 69), the
length of this interval was between 6 and 12 months for
only 14 individuals. The median [interquartile range
(IQR)] viral load at the start of their transient ART was
5.1 (4.5–5.8) log10 copies/ml. Out of 184 pretreated
individuals with viral load measurements available during
their EHI transient treatment, 133 (72%) had less than 50
and 29 (16%) 50–500 HIV-RNA copies/ml before
interrupting treatment.
Virologic response and relapse
Timing and frequency of viral load measurements after
cART initiation in CHI were similar in the two groups,
with the first measurement taken after a median (IQR) of
1.2 (0.9, 2.3) months.
The distribution of viral loads at different time points after
CHI-cART initiation is summarized in Fig. 1a. As shown
in this figure, more than 80% of the treated individuals in
both groups achieved less than 50 copies/ml viral load
levels after the 12th month of treatment. Although the
proportion of individuals with less than 50 copies/ml viral
load appears slightly higher at 6, 18, and 24 months after
cART initiation in CHI in those who were previously
untreated, compared to those pretreated in EHI, such
figures should be interpreted with caution because of
their cross-sectional nature.
The estimated cumulative probabilities of achieving less
than 50 copies/ml viral load are presented in Fig. 1b.
Median [95% confidence interval (CI)] time to virologic
response was similar at 3.42 (2.82, 4.01) and 3.06 (2.94,3.18) months for the pretreated in EHI and previously
untreated group, respectively.
Multivariable analysis (Table 2) did not reveal any
significant difference between the two groups
(P¼ 0.585). Estimated acceleration factors were greater
than 1 for all other risk groups compared to MSM,
indicating longer average times to achieve viral suppres-
sion. A clear trend for higher rates of virologic response to
treatment initiated in more recent years was also evident.
Higher initial viral load levels were associated with longer
times to virologic response. Finally, regimens based on
NNRTIs were associated with better performance as
the average times to achieve viral load undetectability
were shorter compared with those associated with
PI-based regimens.
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Table 2. Differences in (a) virologic response and (b) virologic relapse of HIV-1 seroconverters treated in chronic infection by whether they had
initiated combination antiretroviral treatment within 6 months of seroconversion (pretreated in early HIV infection) or not (not pretreated in
early HIV infection).
(a) Virologic response (b) Virologic relapse
Factor Acceleration factors 95% CI P Acceleration factors 95% CI P
Pretreated in early HIV infection (yes/no) 1.04 (0.90, 1.21) 0.585 1.27 (0.88, 1.85) 0.206
Sex (female/male) 0.63 (0.45, 0.88) 0.007
Risk group
IDU/MSM 1.22 (1.02, 1.47) 0.034 0.33 (0.21, 0.54) <0.001
MSW/MSM 1.09 (1.01, 1.19) 0.037 0.97 (0.73, 1.28) 0.82
Other unknown/MSM 1.28 (1.08, 1.52) 0.004 0.67 (0.42, 1.06) 0.087
Ethnic group
Black/white 0.94 (0.76, 1.16) 0.578 1.08 (0.63, 1.88) 0.776
Hispanic/white 0.98 (0.65, 1.48) 0.926 1.28 (0.41, 3.97) 0.667
Asian/white 0.86 (0.63, 1.18) 0.354 0.71 (0.32, 1.60) 0.413
Mixed other/white 1.14 (0.73, 1.79) 0.569 0.86 (0.24, 3.00) 0.809
Unknown/white 1.09 (1.02, 1.17) 0.008 1.01 (0.84, 1.20) 0.935
Year of CHI cART
2000/2010þ 1.66 (1.46, 1.89) <0.001 0.32 (0.23, 0.44) <0.001
2004/2010þ 1.35 (1.22, 1.51) <0.001 0.47 (0.36, 0.63) <0.001
2006/2010þ 1.21 (1.10, 1.32) <0.001 0.63 (0.49, 0.80) <0.001
2008/2010þ 1.11 (1.02, 1.20) 0.011 0.71 (0.57, 0.88) 0.002
Type of CHI cART
Boosted PI/NNRTI 1.34 (1.25, 1.43) <0.001 0.77 (0.65, 0.91) 0.003
Unboosted PI/NNRTI 1.24 (1.03, 1.50) 0.023 0.74 (0.44, 1.23) 0.246
Other/NNRTI 0.53 (0.45, 0.62) <0.001 0.79 (0.56, 1.12) 0.19
CHI cART baseline RNA (copies/ml)
500/50–499 0.87 (0.66, 1.14) 0.315 1.94 (1.27, 2.97) 0.002
5000/50–499 1.91 (1.50, 2.44) <0.001 2.57 (1.83, 3.60) <0.001
50000/50–499 3.09 (2.41, 3.96) <0.001 1.81 (1.26, 2.61) 0.001
100000þ/50–499 4.14 (3.25, 5.28) <0.001 1.82 (1.29, 2.56) 0.001
Age at CHI-cART (per 10 years) 1.15 (1.06, 1.25) 0.001
P values based on Wald tests from the corresponding models. Results from accelerated failure time models for interval censored data. cART,
combination antiretroviral treatment; CHI, chronic infection; CI, confidence interval; IDU, injection drug users, IQR, interquartile range; MSM,
men who have sex with men; MSW, sex between men and women; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.Approximately 20% of those who achieved virologic
suppression (or initiated cART in CHI with undetectable
viral load) relapsed by the 24th month after the initial
virologic response (Fig. 1c). The estimated cumulative
probabilities (95% CI) of virologic relapse were similar for
the two groups at 0.09 (0.05, 0.12) and 0.11 (0.10, 0.12)
at the 12th month, and 0.16 (0.12, 0.21) and 0.20 (0.18,
0.21) at the 24th month after the initial response for those
pretreated in EHI and those previously untreated,
respectively. After adjusting for other potential con-
founders (Table 2) differences between the two groups
remained nonsignificant (P¼ 0.206). Relapse rates were
higher in men, injecting drug users, those treated in
earlier years and those (re)starting treatment with very
low viral load.
We also found no evidence to suggest that virologic
response or relapse following reinitiation in CHI were
associated with the interval between estimated serocon-
version and cART initiation in EHI (P¼ 0.624 and
P¼ 0.581, respectively). Similarly, there was no evidence
of an effect of the cART duration during EHI (P¼ 0.866
and P¼ 0.844, respectively).
CD4R cell count evolution
The first CD4þ cell count measurement post CHI-cART
initiation was taken after a median (IQR) of 1.3 (0.9, 2.5)months with no significant difference between the
two groups.
The distribution of CD4þ cell count by time and group is
summarized in Fig. 2a. Individuals who had initiated
cART in EHI seem to start their CHI-cART at slightly
higher CD4þ cell counts. CD4þ cell count increases seem
faster during the first 3 months of therapy with decelerating
rates thereafter. CD4þ dynamics seem similar between the
two groups with no marked differences, in terms of CD4þ
cell count slope but, as in Fig. 1a, caution is needed when
interpreting such cross-sectional figures.
Results from a multivariable mixed model are shown in
Table 3. Those pretreated in EHI tend to start their CHI
treatment at higher CD4þ cell counts compared to those
who were previously naive. The estimated average (95%
CI) baseline CD4þ cell counts for the pretreated and
previously naive individuals, for the reference category
(white, MSM, aged 15–29 years at seroconversion,
starting an NNRTI-based regimen after 2009, with
>100 000 HIV-RNA copies/ml), were 460 (434, 486)
and 383 (373, 394) cells/ml, respectively (P< 0.001).
Individuals initiating in CHI had faster CD4þ increases in
general, but the difference was significant only during
months 3–30 after treatment initiation (P¼ 0.015).
Boosted PI-based regimens were associated with faster
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Fig. 2. Cross-sectional distribution of (a) CD4R cell count,
(b) estimated evolution of average CD4R cell count and (c)
estimated evolution of average CD4R cell count assuming a
common baseline of 400 cells/ml after combination antire-
troviral treatment initiation during chronic HIV infection
(CHI) in individuals pretreated (black lines) in early HIV
infection (EHI) and previously untreated (grey lines) indi-
viduals. Vertical lines in (a) denote interquartile range (IQR)
and dashed lines in (b) and (c) are 95% confidence intervals.increases during the first 3 months and injecting drug
users had a worse CD4þ response, compared to men
infected through sex between men throughout the whole
study period. Younger individuals had faster initial CD4þ
cell count increases but this association was reversed after
the first 3 months of treatment. Finally, individuals of
black or Hispanic ethnicity had lower CD4þ cell counts at
baseline, compared with white individuals, whereas
higher baseline plasma viral load levels were associated
with lower baseline CD4þ cell count but faster increases
after treatment initiation.
The time interval between seroconversion and initiation
of treatment in EHI for the pretreated group did notsignificantly affect the initial CD4þ cell count at
treatment initiation in CHI or the subsequent rates of
CD4þ cell count increase (P¼ 0.722). The duration of
the transient EHI treatment was positively associated with
the baseline CD4þ cell counts at CHI treatment initiation
(P¼ 0.020) but had no significant effect on the
subsequent CD4þ slopes (P> 0.100 for all three slopes).
The average CD4þ cell count evolution for the reference
category (as previously described) is shown in Fig. 2b.
Those initiating in CHI had slightly faster CD4þ cell
count increases, compared to those who had initiated in
EHI, but their CD4þ cell levels remain lower, even after
3 years of treatment (estimated difference: 51 CD4þ cells/
ml; P¼ 0.007). However, as pretreated individuals restart
treatment in CHI at higher CD4þ cell count compared
to those who were initiating in CHI, we applied a
postestimation adjustment assuming individuals in both
groups re(initiate) treatment at the same CD4þ cell count
level (i.e., 400 CD4þ cells/ml). As can be seen in Fig. 2c,
those initiating in CHI seem to maintain slightly higher
CD4þ cell counts compared with those pretreated during
EHI, but there is a large degree of overlap in the
corresponding 95% CIs, indicating that differences are
not significant (P¼ 0.077).Discussion
Our study assessed virologic and immunologic outcomes
of long-term cART, initiated during CHI, in persons
who were pretreated with transient cART during EHI
compared with those who initiated in CHI. Our findings
suggest that prior treatment during EHI has no effect on
virologic response or relapse following reinitiation of
long-term cART. Pretreated individuals reinitiated cART
in CHI at approximately 80 cells/ml higher CD4þ cell
count than those initiating in CHI. Even though the
subsequent rate of CD4þ cell count increase was slightly
slower for those who had previously been treated in EHI;
they retained higher CD4þ cell counts even after 3 years
of treatment. However, assuming a common baseline
CD4þ cell count, the estimated difference between the
two groups was not significant after 3 years of treatment.
Duration of transient cART in EHI and its timing relative
to estimated seroconversion did not appear to have any
significant effect on virologic or immunologic outcome
of long-term cART in CHI. We cannot rule out,
however, that shorter cART duration in EHI would have
adversely affected outcome following reinitiation in CHI.
The main strength of our study is its size and length of
follow-up. To our knowledge, this is the largest study
focusing on this comparison, including 202 pretreated
and 4263 previously untreated individuals with a median
follow-up, after the initiation of treatment in CHI, of
approximately 4.5 and 3 years, respectively. Given that
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886 AIDS 2016, Vol 30 No 6this is an observational study, efforts have been made to
minimise the effect of bias. For example, we excluded
individuals who received cART in EHI because of low
CD4þ cell counts or AIDS. Moreover, all comparisons
were based on multivariable models which included
adjustments for potential confounders. Finally, the study
population is drawn from a number of countries (mainly
in Europe, but also Australia and Canada), and includes
individuals who had acquired HIV through both sex
between men, and sex between men and women, and
regimens used for long-term cARTwere equally based on
the two most common antiretroviral classes (i.e.,
NNRTIs and boosted PIs).
Despite our restrictions regarding the time interval
between the last negative and first-positive HIV test dates,
a substantial proportion of individuals (mainly among
those who initiated cART during chronic infection) had
an HIV test window between 30 days and 1 year, allowing
for some uncertainty regarding the exact time of
seroconversion. It is noteworthy though that, for almost
two-thirds of the pretreated individuals, the accuracy in
the estimation of the seroconversion date was excellent
and most of them initiated their transient treatment very
soon after their seroconversion, having viral loads which
were much higher compared to typical set-point levels.
Thus, although we did not specifically aim to study
individuals treated during acute infection, a substantial
proportion of the pretreated individuals started cART
very close to the time of seroconversion and this allowed
us to investigate whether the gap between seroconversion
and ART initiation modified our findings.
Additionally, reasons for starting and stopping treatment
in EHI were not available. It should be noted though that
the frequency of seroconversion illnesses was low, and
similar in both groups, and that those who started
treatment in EHI because of an AIDS diagnosis and/or
low CD4þ cell counts have been excluded. Furthermore,
virological failure does not appear to account for the
interruption of early treatment as almost 90% of
pretreated individuals interrupted with HIV-RNA less
than 500 copies/ml.
Even though differences in available factors with a
significant effect on virologic and/or immunologic
response were taken into account, residual confounding
cannot be ruled out, as in all observational studies.
Moreover, we were not able to examine differences
between groups in terms of proinflammation and
coagulation markers, HIV reservoir size, or CD4þ/
CD8þ ratio normalization, thus our findings should be
interpreted with caution.
Our main results are in agreement with those reported by
the Short Pulse Anti Retroviral Therapy at HIV
Seroconversion trial investigators [16]. As in our study,
individuals randomized to 12 or 48 weeks of transientcART within 6 months from seroconversion had similar
virologic and CD4þ responses in long-term cART
initiated in CHI with those who remained untreated
during EHI. In a smaller study, Grijsen and colleagues
[32] compared 36 ART-naive and 132 individuals who
were pretreated in EHI and found no differences between
them in terms of virologic and CD4þ cell count response.
Notably, in the same study it was found that transient
treatment in EHI was not associated with clinically
relevant drug resistance mutations.
Guidelines regarding the optimal clinical management
of EHI were for many years, and partly remain, unclear
[26–28]. However, there is accumulated evidence
supporting the hypothesis that intervening as soon as
possible after HIV infection may lead to clinical benefit or
even remission of the disease in a small number of cases
[6–9,13,23,24,33]. Despite these encouraging findings,
the proportion of early treated individuals who maintain
long-term viral suppression after treatment cessation is very
small. A recent meta-analysis [34] summarized the results of
eight relevant studies and found that ‘immunovirological
benefits declined gradually after treatment interruption,
reaching no statistical significance after 12–24 months’.
As HIV treatment guidelines have successively recom-
mended cART initiation at higher CD4þ cell count
thresholds [26–28], and the latest evidence from the
INISGHT-START trial [35] clearly supports the
initiation of treatment in all HIV-positive individuals,
irrespectively of their CD4þ cell count, a significant
number of individuals will likely be initiating cART in
EHI. We may anticipate a substantial proportion of them
to interrupt, who will need to reinitiate later during
chronic infection. Thus, it is clinically relevant to assess
the effects of this early intervention on the outcomes of
long-term treatment. According to our findings, indi-
viduals who initiate, and then stop, cART within
6 months of seroconversion do not fare differently from
those who initiate in CHI, at least in terms of viral load
and CD4þ cell count post-cART changes.
Treatment interruption during CHI is associated with
poorer prognosis [5,36] and clearly not recommended by
current guidelines [26,27]. Our data suggest, in agree-
ment with others, that interrupting cART initiated in
EHI does not have a detrimental effect on the
immunovirologic response to long-term treatment in
CHI. Intervening during EHI to suppress viral load,
during a period which is characterized by markedly
higher risk of HIV transmission, could have a positive
impact in terms of public health [37]. Without evidence
regarding the safety and consequences of interrupting
treatment initiated in EHI and restarting it later, this
strategy should be avoided. Our findings, nonetheless,
provide helpful insights for those designing cure studies
which necessitate stopping cART initiated in EHI to
assess the degree of viral remission.
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